These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

158 related articles for article (PubMed ID: 8189828)

  • 1. [Susceptibility of Clostridium difficile strains to teicoplanin and ramoplanin].
    Dworczyński A; Martirosian G; Meisel-Mikołajczyk F
    Med Dosw Mikrobiol; 1993; 45(4):483-6. PubMed ID: 8189828
    [TBL] [Abstract][Full Text] [Related]  

  • 2. In-vitro activity of vancomycin, teicoplanin, daptomycin, ramoplanin, MDL 62873 and other agents against staphylococci, enterococci and Clostridium difficile.
    Bartoloni A; Colao MG; Orsi A; Dei R; Giganti E; Parenti F
    J Antimicrob Chemother; 1990 Nov; 26(5):627-33. PubMed ID: 1688341
    [TBL] [Abstract][Full Text] [Related]  

  • 3. In vitro activities of ramoplanin, teicoplanin, vancomycin, linezolid, bacitracin, and four other antimicrobials against intestinal anaerobic bacteria.
    Citron DM; Merriam CV; Tyrrell KL; Warren YA; Fernandez H; Goldstein EJ
    Antimicrob Agents Chemother; 2003 Jul; 47(7):2334-8. PubMed ID: 12821492
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Antibacterial activity of teicoplanin against Clostridium difficile.
    Wongwanich S; Kusum M; Phan-Urai R
    Southeast Asian J Trop Med Public Health; 1996 Sep; 27(3):606-9. PubMed ID: 9185278
    [TBL] [Abstract][Full Text] [Related]  

  • 5. In vitro activity of ramoplanin on staphylococci.
    Francis J; Webster H; Newsom SW
    Drugs Exp Clin Res; 1990; 16(9):457-60. PubMed ID: 2100247
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Comparison of the efficacy of ramoplanin and vancomycin in both in vitro and in vivo models of clindamycin-induced Clostridium difficile infection.
    Freeman J; Baines SD; Jabes D; Wilcox MH
    J Antimicrob Chemother; 2005 Oct; 56(4):717-25. PubMed ID: 16143709
    [TBL] [Abstract][Full Text] [Related]  

  • 7. In vitro activities of ramoplanin and four glycopeptide antibiotics against clinical isolates of Clostridium difficile.
    Biavasco F; Manso E; Varaldo PE
    Antimicrob Agents Chemother; 1991 Jan; 35(1):195-7. PubMed ID: 1826593
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Antibiotic resistance of Clostridium difficile isolates.
    Dworczyński A; Sokół B; Meisel-Mikołajczyk F
    Cytobios; 1991; 65(262-263):149-53. PubMed ID: 1828756
    [TBL] [Abstract][Full Text] [Related]  

  • 9. In vitro activity of ramoplanin against Clostridium difficile, including strains with reduced susceptibility to vancomycin or with resistance to metronidazole.
    Peláez T; Alcalá L; Alonso R; Martín-López A; García-Arias V; Marín M; Bouza E
    Antimicrob Agents Chemother; 2005 Mar; 49(3):1157-9. PubMed ID: 15728918
    [TBL] [Abstract][Full Text] [Related]  

  • 10. In vitro susceptibility of genotypically distinct and clonal Clostridium difficile strains to oritavancin.
    O'Connor R; Baines SD; Freeman J; Wilcox MH
    J Antimicrob Chemother; 2008 Oct; 62(4):762-5. PubMed ID: 18606787
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Susceptibility of Clostridium difficile toward antimicrobial agents used as feed additives for food animals.
    Aarestrup FM; Tvede M
    Microb Drug Resist; 2011 Mar; 17(1):125-7. PubMed ID: 20950192
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Analysis of anti-Clostridium difficile activity of thuricin CD, vancomycin, metronidazole, ramoplanin, and actagardine, both singly and in paired combinations.
    Mathur H; O'Connor PM; Hill C; Cotter PD; Ross RP
    Antimicrob Agents Chemother; 2013 Jun; 57(6):2882-6. PubMed ID: 23571539
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Efficacy of daptomycin compared to teicoplanin in the treatment of Clostridium difficile colitis in hamsters.
    Nord CE; Lindmark A; Persson I
    J Chemother; 1989 Jul; 1(4 Suppl):209-10. PubMed ID: 16312372
    [No Abstract]   [Full Text] [Related]  

  • 14. In-vitro activity of ramoplanin (a novel lipoglycopeptide), vancomycin, and teicoplanin against gram-positive clinical isolates from cancer patients.
    Rolston KV; Dholakia N; Ho DH; LeBlanc B; Dvorak T; Streeter H
    J Antimicrob Chemother; 1996 Aug; 38(2):265-9. PubMed ID: 8877541
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Ambush of Clostridium difficile spores by ramoplanin: activity in an in vitro model.
    Kraus CN; Lyerly MW; Carman RJ
    Antimicrob Agents Chemother; 2015 May; 59(5):2525-30. PubMed ID: 25691641
    [TBL] [Abstract][Full Text] [Related]  

  • 16. The in vitro activity of ramoplanin (A-16686/MDL 62,198), vancomycin and teicoplanin against methicillin-susceptible and methicillin-resistant Staphylococcus spp.
    O'Hare MD; Felmingham D; Grüneberg RN
    Drugs Exp Clin Res; 1988; 14(10):617-9. PubMed ID: 2977587
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Antimicrobial activity of LFF571 and three treatment agents against Clostridium difficile isolates collected for a pan-European survey in 2008: clinical and therapeutic implications.
    Debast SB; Bauer MP; Sanders IM; Wilcox MH; Kuijper EJ;
    J Antimicrob Chemother; 2013 Jun; 68(6):1305-11. PubMed ID: 23420839
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Comparison of the in vitro activities of teicoplanin and vancomycin against Clostridium difficile and their interactions with cholestyramine.
    Pantosti A; Luzzi I; Cardines R; Gianfrilli P
    Antimicrob Agents Chemother; 1985 Dec; 28(6):847-8. PubMed ID: 2935077
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Typing and susceptibility of bacterial isolates from the fidaxomicin (OPT-80) phase II study for C. difficile infection.
    Citron DM; Babakhani F; Goldstein EJ; Nagaro K; Sambol S; Sears P; Shue YK; Gerding DN
    Anaerobe; 2009 Dec; 15(6):234-6. PubMed ID: 19755166
    [TBL] [Abstract][Full Text] [Related]  

  • 20. [Antimicrobial activity of oral quinolones against clinical isolates of Bifidobacterium group and Clostridium difficile].
    Kimura M; Yamagishi Y; Terada M; Ohki E; Tanaka K; Watanabe K; Mikamo H
    Jpn J Antibiot; 2010 Apr; 63(2):171-7. PubMed ID: 20919497
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.